Capital Investment Advisors LLC Buys 16,620 Shares of Johnson & Johnson (NYSE:JNJ)

Capital Investment Advisors LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.1% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 425,033 shares of the company's stock after acquiring an additional 16,620 shares during the quarter. Johnson & Johnson comprises about 1.4% of Capital Investment Advisors LLC's portfolio, making the stock its 13th biggest holding. Capital Investment Advisors LLC's holdings in Johnson & Johnson were worth $70,488,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of the stock. Hickory Point Bank & Trust lifted its position in shares of Johnson & Johnson by 10.6% during the 1st quarter. Hickory Point Bank & Trust now owns 2,774 shares of the company's stock valued at $460,000 after acquiring an additional 265 shares during the period. PFW Advisors LLC lifted its position in shares of Johnson & Johnson by 0.7% during the 1st quarter. PFW Advisors LLC now owns 14,571 shares of the company's stock valued at $2,416,000 after acquiring an additional 98 shares during the period. Lloyd Advisory Services LLC. bought a new stake in shares of Johnson & Johnson during the 1st quarter worth $226,000. Bennett Selby Investments LP lifted its position in shares of Johnson & Johnson by 0.9% during the 1st quarter. Bennett Selby Investments LP now owns 17,558 shares of the company's stock worth $2,912,000 after buying an additional 148 shares during the last quarter. Finally, Park Avenue Securities LLC lifted its position in shares of Johnson & Johnson by 29.4% during the 1st quarter. Park Avenue Securities LLC now owns 100,307 shares of the company's stock worth $16,635,000 after buying an additional 22,768 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $155.02 on Monday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $372.99 billion, a PE ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42. The stock has a 50-day moving average price of $153.59 and a two-hundred day moving average price of $153.67.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.35%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Raymond James dropped their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Finally, Morgan Stanley upped their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.